CHMA News and Press, Chiasma Inc. From 11/18/20

Chiasma (CHMA) perks 6% premarket after announcing positive top-line data from its global Phase 3 MPOWERED non-inferiority clinical trial comparing Mycapssa (oral octreotide capsules) to long-acting injectable somatostatin analogs (SSAs) for maintenance of biochemical response in pa...

91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial C ompany intends to submit a marketing application for MYCAPSSA in the EU in mid-2021 Company...

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful i...

Image source: The Motley Fool. Chiasma (NASDAQ: CHMA) Q3 2020 Earnings Call Nov 05, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Chiasma (CHMA) Q3 2020 Earnings Call Transcript

Chiasma (CHMA): Q3 GAAP EPS of -$0.30 beats by $0.09.Revenue of $0.14MPress Release For further details see: Chiasma EPS beats by $0.09

L aunched MYCAPSSA ® in U.S. earlier than expected and recognized first net product revenues in September Well capitalized to support the MYCAPSSA launch On track to announce MPOWERED ™ Phase 3 trial topline data ...

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to people with acromegaly and the patient advocacy groups in their ongoing efforts to increase ...

NEEDHAM, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00 pm Eastern Time to discuss financial results for the...

A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) leve...

Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%. For further details see: CORR, FATE, AKBA and DPW among after-hours movers